Sex differences in LDL-C response to PCSK9 inhibitors: A real world experience

Low-density lipoprotein cholesterol (LDL-C) is a well-established and important cardiovascular risk factor. HMG-CoA reductase inhibitor (statin) therapy is the first line of lipid-lowering treatment for atherosclerotic cardiovascular disease (ASCVD) risk reduction.1-3 In the IMPROVE-IT trial, the addition of ezetimibe to statin therapy has also demonstrated a significant, if modest, additional clinical benefit on ASCVD risk reduction.4 However, residual CV risk remains a major concern. Indeed, according to results from the HELLAS-FH registry, LDL-C target attainment using the 2019 ESC/EAS guidelines was 2.7%.
Source: Journal of Clinical Lipidology - Category: Lipidology Authors: Tags: Original Research Source Type: research